Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Ovarian Neoplasms 3Hodgkin Disease 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Glioma 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Hyperplasia 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Calcinosis 1Breast Neoplasms 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Cyclophosphamide 125Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 81Etoposide 73Filgrastim 64Mycophenolic Acid 63Tacrolimus 57Whole-Body Irradiation 55Busulfan 52Doxorubicin 50Radiotherapy 48Melphalan 48Cyclosporine 47Brentuximab Vedotin 45Rituximab 39Vinblastine 37fludarabine 36Granulocyte Colony-Stimulating Factor 36Antilymphocyte Serum 35Prednisone 33Methotrexate 32Vincristine 31Gemcitabine 30Dacarbazine 29Bleomycin 29Cytarabine 26Carmustine 22Bendamustine Hydrochloride 21Sirolimus 18Ifosfamide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hodgkin Disease × Pharmacogenomic Variants × Clear all
NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1 Completed
50 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

City of Hope Medical Center

Phase 1 Completed
29 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡